<?xml version="1.0" encoding="UTF-8"?>
<p>The current global clinical pipeline of TB vaccine candidates utilizes a limited number of the approximately 4,000 
 <italic>Mtb</italic> antigens. A critical question is whether the optimal antigens are being selected for inclusion in protein subunit and recombinant viral vaccines. In a large phase 2b trial of the MVA85A vaccine in South African infants, the vaccine did not provide significant additional protection above BCG vaccination 
 <sup>
  <xref rid="ref-66" ref-type="bibr">66</xref>
 </sup>. A possible explanation for this outcome is that Ag85A, although highly immunogenic, may not have been the right antigen given that its expression is downregulated later in infection and may not be presented sufficiently by infected cells.
</p>
